Prevalence of Factor V Leiden Mutation in Yugoslav Thrombophilic Patients and Its Relationship to the Laboratory Diagnosis of APC Resistance

Thromb Haemost 2000; 84(04): 723-724
DOI: 10.1055/s-0037-1614094

Letters to the Editor

Schattauer GmbH

Danijela Mikovic

¹The Heamostasis Department and Hemophilia Center, National Blood Transfusion Institute, Belgrade

,

Ljiljana Rakicevic

²Institute Molecular Genetics and Genetics Engineering, Belgrade, Yugoslavia

,

Mirjana Kovac

¹The Heamostasis Department and Hemophilia Center, National Blood Transfusion Institute, Belgrade

,

Dragica Radojkovic

²Institute Molecular Genetics and Genetics Engineering, Belgrade, Yugoslavia

References
1 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in the majority of thrombophilic patients. Blood 1993; 82: 1989-93.
2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
3 Bertina RM, Koeleman BPC, Koster T, Rosendal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
4 Dahlback B. Resistance to activated protein C caused by the factor VR⁵⁰⁶Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-8.
5 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
6 Moerloose P, Bounemaux HR, Mannucci PM. Screening Tests for Thrombophilic Patients: Which Tests, for which Patient, by Whom, When, and Why?. Semin Thromb Hemost 1998; 24 (04) 321-7.
7 Bertina MR. Laboratory Diagnosis of Resistance to Activated Protein C (APC-Resistance). Thromb Haemost 1997; 78 (01) 478-82.
8 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg 306→Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.